^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tivdak (tisotumab vedotin-tftv)

    i
    Company:
    Genmab, Pfizer, ZAI Lab
    Drug class:
    Microtubule inhibitor, Human TF-targeted antibody-drug conjugate
    Related drugs:
    Apply
    Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (KEYNOTE-E02) (NCT03485209)
    Phase 2
    Seagen Inc.
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/25/2018
    Primary completion :
    04/30/2025
    Completion :
    11/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Tivdak (tisotumab vedotin-tftv)
    A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) (NCT03657043)
    Phase 2
    Seagen Inc.
    Completed
    Last update posted :
    05/04/2023
    Initiation :
    03/20/2019
    Primary completion :
    02/08/2022
    Completion :
    02/08/2022
    MUC16
    |
    Tivdak (tisotumab vedotin-tftv)
    Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors (NCT02001623)
    Phase 1/2
    Seagen Inc.
    Completed
    Last update posted :
    12/29/2021
    Initiation :
    11/30/2013
    Primary completion :
    05/02/2019
    Completion :
    05/02/2019
    MUC16
    |
    Tivdak (tisotumab vedotin-tftv)
    Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors (NCT02552121)
    Phase 1/2
    Seagen Inc.
    Completed
    Last update posted :
    04/08/2021
    Initiation :
    11/30/2015
    Primary completion :
    12/13/2017
    Completion :
    12/13/2017
    MUC16
    |
    Tivdak (tisotumab vedotin-tftv)